In The News,
U.S. Respiratory Syncytial Virus (RSV) Vaccine
Informed the client about clinical trial strategy to optimize a positive ACIP recommendation and prepare for key access risks and opportunities for an RSV vaccine, leveraging ADVI’s deep expertise in US pricing and market access trends and work experience with ACIP/CDC.
Interested in hearing more from us?
Receive customized email alerts from the ADVI team